Cargando…
Cystic brain metastases in ALK-rearranged non-small cell lung cancer
The central nervous system (CNS) is a common site of disease progression in patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearrangement treated with crizotinib. Cystic brain metastases (CBM) have been recently identified as one possible variant of this diseas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880229/ https://www.ncbi.nlm.nih.gov/pubmed/29662531 http://dx.doi.org/10.3332/ecancer.2018.818 |
_version_ | 1783311126694461440 |
---|---|
author | Marta, Guilherme Nader da Cunha Colombo Bonadio, Renata Rodrigues Martins, Renata Eiras Zuppani, Henrique Bortot de Castro, Gilberto |
author_facet | Marta, Guilherme Nader da Cunha Colombo Bonadio, Renata Rodrigues Martins, Renata Eiras Zuppani, Henrique Bortot de Castro, Gilberto |
author_sort | Marta, Guilherme Nader |
collection | PubMed |
description | The central nervous system (CNS) is a common site of disease progression in patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearrangement treated with crizotinib. Cystic brain metastases (CBM) have been recently identified as one possible variant of this disease. An illustrative case report is presented along with a literature review performed in order to track relevant papers about CBM in ALK-rearranged NSCLC, including possible pathophysiology, differential diagnosis and treatment options for this condition. Three case reports have been published describing six ALK-rearranged NSCLC patients presenting with CBM, all of which were under treatment with crizotinib by the time of CBM diagnosis. Treatment with CNS-penetrating tyrosine kinase inhibitors (TKIs) resulted in CNS disease control in three of the six cases reported either as single therapy or in combination with radiation therapy (RT). Investigation of differential diagnoses of CBM might be necessary, which include inflammatory and demyelinating disorders, primary brain tumours and infectious diseases, especially neurocysticercosis that might mimic CBM images. Treatment options include RT, CNS-penetrating TKIs and invasive procedures, such as stereotactic drainage. Thus, CBM are associated with ALK-rearranged NSCLC, particularly in patients who use crizotinib and should prompt investigation of differential diagnosis. CNS-penetrating TKIs are effective in the control of solid brain metastases and also seem to be active in CBM as single therapy or in combination with RT. |
format | Online Article Text |
id | pubmed-5880229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-58802292018-04-16 Cystic brain metastases in ALK-rearranged non-small cell lung cancer Marta, Guilherme Nader da Cunha Colombo Bonadio, Renata Rodrigues Martins, Renata Eiras Zuppani, Henrique Bortot de Castro, Gilberto Ecancermedicalscience Review The central nervous system (CNS) is a common site of disease progression in patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK)-rearrangement treated with crizotinib. Cystic brain metastases (CBM) have been recently identified as one possible variant of this disease. An illustrative case report is presented along with a literature review performed in order to track relevant papers about CBM in ALK-rearranged NSCLC, including possible pathophysiology, differential diagnosis and treatment options for this condition. Three case reports have been published describing six ALK-rearranged NSCLC patients presenting with CBM, all of which were under treatment with crizotinib by the time of CBM diagnosis. Treatment with CNS-penetrating tyrosine kinase inhibitors (TKIs) resulted in CNS disease control in three of the six cases reported either as single therapy or in combination with radiation therapy (RT). Investigation of differential diagnoses of CBM might be necessary, which include inflammatory and demyelinating disorders, primary brain tumours and infectious diseases, especially neurocysticercosis that might mimic CBM images. Treatment options include RT, CNS-penetrating TKIs and invasive procedures, such as stereotactic drainage. Thus, CBM are associated with ALK-rearranged NSCLC, particularly in patients who use crizotinib and should prompt investigation of differential diagnosis. CNS-penetrating TKIs are effective in the control of solid brain metastases and also seem to be active in CBM as single therapy or in combination with RT. Cancer Intelligence 2018-03-14 /pmc/articles/PMC5880229/ /pubmed/29662531 http://dx.doi.org/10.3332/ecancer.2018.818 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Marta, Guilherme Nader da Cunha Colombo Bonadio, Renata Rodrigues Martins, Renata Eiras Zuppani, Henrique Bortot de Castro, Gilberto Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title | Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title_full | Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title_fullStr | Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title_full_unstemmed | Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title_short | Cystic brain metastases in ALK-rearranged non-small cell lung cancer |
title_sort | cystic brain metastases in alk-rearranged non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880229/ https://www.ncbi.nlm.nih.gov/pubmed/29662531 http://dx.doi.org/10.3332/ecancer.2018.818 |
work_keys_str_mv | AT martaguilhermenader cysticbrainmetastasesinalkrearrangednonsmallcelllungcancer AT dacunhacolombobonadiorenatarodrigues cysticbrainmetastasesinalkrearrangednonsmallcelllungcancer AT martinsrenataeiras cysticbrainmetastasesinalkrearrangednonsmallcelllungcancer AT zuppanihenriquebortot cysticbrainmetastasesinalkrearrangednonsmallcelllungcancer AT decastrogilberto cysticbrainmetastasesinalkrearrangednonsmallcelllungcancer |